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COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY
VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM’S
PERSPECTIVE IN AUSTRIA
Tuschel A, Meissl M, Ogon M
Orthopaedic Hospital Vienna Speising,Vienna, Austria
OBJECTIVES: Chronic low back pain caused by disc degen-
eration (“degenerative disc disease”) is one of the most
common causes for doctor visits in western industrial countries
and presents an immense economic burden both to the indi-
vidual and to society. In many cases, surgery can be a treatment
option. For some indications, “lumbar disc arthroplasty” may
be an innovative alternative to the current gold-standard,
“lumbar fusion” and recent clinical studies have shown at least
its non-inferiority for short- and midterm follow-up The aim of
this investigation was to analyse cost-effectiveness of “lumbar
disc arthroplasty” versus “lumbar fusion” form a health care
system’s perspective. METHODS: A decision model including
treatment paths and associated direct costs (surgery, inpatient
stays, outpatient visits, GP and orthopaedic consultations,
x-ray, medication, rehabilitation and physiotherapy) over a
12-months time horizon was developed. Main outcomes were
clinical success (measured by Oswestry-Disability-Index (ODI)
and SF-36 at 1 year follow-up) and costs in Euros (€). Clinical
input data was derived from a recently performed matched-
cohort-study and a meta-analysis of further four trials com-
paring the two treatment options. Costs were derived from
standard Austrian price lists and from hospital’s cost unit
accounting. RESULTS: Disc arthroplasty showed statistically
signiﬁcant better outcome-scores at 1 year-follow up, while at
the same time caused lower costs than lumbar fusion: Costs per
improved ODI-point were 918€ in the fusion group and €519
in patients treated with lumbar disc arthroplasty. Costs for one
gained SF36-point were €1500 after fusion and €866€ after disc
arhroplasty. CONCLUSIONS: For a period of 1 year after
surgery, this study suggests that lumbar disc arthroplasty is a
cost-effective treatment compared with lumbar fusion from a
health care system’s perspective in Austria. Further studies,
including longer follow-up and indirect-costs, are necessary
for the assessment of cost-effectiveness from the societal
perspective.
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UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS
WITH STROKE OF UNDETERMINED AETIOLOGY:
COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC
MONITORS (ICMS)TOTHE DIAGNOSTIC PATHWAY
Murthy A1,Tsintzos S2
1Medtronic International,Tolochenaz,Vaud, Switzerland,
2Medtronic International Trading Sarl,Tolochenaz,Vaud, Switzerland
OBJECTIVES: Managing stroke of undetermined aetiology (or
“cryptogenic stroke”) poses complex therapeutic decisions for
physicians. In the absence of a clear diagnosis, effective measures
of preventing stroke recurrence may be missed. AF is estimated to
be present in a signiﬁcant portion of these patients. Adding an
ICM to standard diagnostics allows physicians to maximize AF
detection yield, administer targeted and appropriate care, and
efﬁciently prevent stroke recurrence. We sought to examine the
cost-effectiveness of this strategy, under the UK NHS setting.
METHODS: Literature Review of OAC Usage and HRQoL
Effects; Stroke HRQoL Effects; and, AF Monitoring and Costs.
TreeAge Pro Version 8 was used to develop a Markov Decision
Model, analysed using Monte Carlo simulations. The payer per-
spective was used. Cost calculations based on UK NHS Reference
Costs. RESULTS: Depending on the year of the analysis, the
ICM-based strategy ranged from highly cost-effective to domi-
nant. The total costs associated with the ICM-based strategy
were £24,278 vs. £28,062 for standard practice. The total effect
of the ICM-based strategy was 14,623 QALYs vs. 14,107
QALYs. CONCLUSIONS: Using ICMs to diagnose AF in
patients with stroke of unknown aetiology dominates current
practice even if all such patients receive a device. Therefore, there
can be little doubt that using these devices to uncover AF within
the studied population can potentially be highly cost-effective.
Moving forward, further research is required to identify the
speciﬁc patient sub-groups in which implanting the ICM
combines maximized economic value with practicality and
affordability.
PODIUM SESSION I: PERFORMANCE OF
HTA AGENCIES
HT1
A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS,
PROCEDURES,AND IMPACT ACROSS HTA AGENCIES
Schwarzer R, Siebert U
UMIT—University for Health Sciences, Medical Informatics and
Technology, Hall i.T,Tirol, Austria
OBJECTIVES: 1) To develop a systematic framework for
describing and comparing different features of HTA agencies in a
formal and explicit manner; 2) to summarize and categorize these
features for selected HTA agencies; 3) to describe and discuss
similarities and differences between the agencies by comparison;
and 4) to draw conclusions both for producers and users of HTA
in research, policy and practice. METHODS: We performed a
systematic literature search, added information from HTA
agencies and developed a conceptual framework comprising
eight main domains: 1) organization; 2) scope; 3) processes; 4)
methods; 5) dissemination; 6) decision; 7) implementation; and
8) impact. We grouped relevant subunits of these domains in an
evidence table. We chose ﬁve HTA agencies to test our frame-
work: IQWiG, DAHTA@DIMDI, NICE, HAS and SBU. The
results were interpreted within and compared across agencies by
demonstrating similarities and differences. RESULTS: We devel-
oped a framework representing a comprehensive structure sur-
rounding HTA and the stages through which a HTA is passing
from science to policy and then impacts the population. We
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identiﬁed 88 aspects as subunits of eight main domains. Agencies
show most similarities in the domain ‘organization’ (4 of 15
subunits), followed by ‘dissemination’ (2 of 9), ‘methods’ (2 of
20), ‘processes’ (1 of 11), and, scope’ (1 of 13). All subunits of
the domains ‘decision’, ‘implementation’ and ‘impact’ were dif-
ferent. Ranking in terms of productivity is misleading without
taking into account other aspects. CONCLUSIONS: We found
considerably more differences than similarities across agencies
and countries inﬂuenced by contextual aspects. This elementary
framework is intended to provide disaggregated and global com-
parative insight that may allow further progress in clariﬁcation
on the need for action regarding harmonization. By enlarging the
number of agencies assessed, our ﬁndings could facilitate the
communication between producers and users in an understand-
able, interpretable and transferable way.
HT2
UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE
TECHNOLOGY APPRAISALS—ECONOMIC CRITICISMS
Karia R, Plested M, Cann K, Zwaferink H
Heron Evidence Development Ltd, Letchworth Garden City, UK
OBJECTIVES: The Single Technology Appraisal (STA) system
has attempted to shorten the process of assessment. As a
follow-up to a previous ISPOR poster, we sought to update the
database with since published STAs as well as conduct further
qualitative research and investigate the criticisms on the eco-
nomic aspects of the submissions. Discrepancies between ICERs
obtained by the manufacturer and the ERG group, and their
impact on outcomes were assessed. METHODS: A previously
developed database was updated with data from submissions
appraised between 6 December 2006 and 31 May 2008. Top-line
clinical data was extracted from the manufacturer submission,
evidence review group report, expert submission and the ﬁnal
appraisal determination. Further qualitative data was gathered to
capture criticisms on the economic aspects of the submissions.
Differences in ICER values between the manufacturer and the
ERG group were also collected. RESULTS: In total, 18 STAs
have been submitted to and appraised by NICE. Thirteen of the
18 submissions received positive guidance from NICE, recom-
mending the use of the drug in the NHS. Further investigation
into criticisms on the economic aspect revealed under-estimation
of costs, exclusion of relevant costs and/or adverse events and
concerns over the time horizon implemented resulting in an
under-estimation of the ICER, commonly leading to negative
guidance. Industry submissions reported ICERs ranging from
£4,726.00 to £44,600.00. Corresponding ICERs reported by the
ERG ranged from £8,500.00 to £458,000.00. The committee
provided positive guidance in approximately 50% of cases, even
though the ERG expressed concerns regarding aspects of the
economic model. CONCLUSIONS: Results demonstrated dis-
crepancies in ICERs between the manufacturer’s submission and
the ERG report. Fifty percent of the submissions received positive
guidance irrespective of concerns voiced by the ERG. Analyzing
criticisms on economic aspects of submissions alongside the ﬁnal
outcome will assist in educating manufacturers in the expecta-
tions of NICE.
HT3
A COMPARISON OF REASONS FOR RECOMMENDATION AND
REJECTION IN FOUR HEALTHTECHNOLOGY APPRAISAL
SYSTEMS: NICE, SMC, CADTH AND PBAC
Cann K, Karia R, Plested M, Samuels E
Heron Evidence Development Ltd, Letchworth Garden City, UK
OBJECTIVES: Technology appraisal systems are used in many
countries to assess newly licensed drug treatments and devices.
Our objective was to identify the reasons underlying recent drug
appraisal decisions in four countries (England/Wales, Scotland,
Canada and Australia) where decisions differed between the
agencies. METHODS: Submissions appraised between 1 Novem-
ber 2005 and 31 May 2008 by NICE, SMC, CADTH and PBAC,
in England/Wales, Scotland, Canada and Australia respectively,
were searched for submissions with opposing decision outcomes.
We compared qualitatively and quantitatively the reasons for
rejection or recommendation for all drugs where decision out-
comes differed between HTA bodies. RESULTS: A total of 81
submissions were identiﬁed as having been appraised by two or
more of the HTA bodies with differing decision outcomes for the
same indication. Seven were excluded from the analysis due to
unavailability of data. The most common reasons given for rec-
ommendation of a drug were cost-effectiveness, superior efﬁcacy
to placebo, and superior efﬁcacy to comparators in 28, 14 and 13
submissions respectively. The most common reasons given for
rejection of a drug were a lack of cost-effectiveness, limitations
identiﬁed in the economic model submitted by the manufacturer,
and a lack of superior efﬁcacy to its comparators, as given in 21,
20 and 10 submissions respectively. Twenty-ﬁve of the submis-
sions highlighted the same issues pertaining to the new drug as
another HTA with a different decision outcome, but continued to
issue an alternative outcome. CONCLUSIONS: Commonly HTA
bodies focus on the relative cost-effectiveness and efﬁcacy of a
new drug. However, different HTAs place different emphases on
each aspect of a submission. Recognising the individual prefer-
ences of the appropriate body could potentially inﬂuence future
outcomes.
HT4
HEALTHTECHNOLOGY ASSESSMENTS:ARETHEY RELEVANT
TO CLINICAL PRACTICE?
Zhang B1,Van Staa TP2
1General Practice Research Database, London, Middlesex, UK,
2General Practice Research Database, London, UK
OBJECTIVES: Data from randomised clinical trials (RCT) are
often considered best evidence for health technology assessments.
The objective of this study was to compare event probabilities
used in published cost-effectiveness studies to those observed in
actual clinical practice. Selective Cox-2 inhibitors (coxibs) were
used as an example. Almost all the 30 published coxib cost-
effectiveness studies used RCT data for event probabilities.
METHODS: A basic cost-effectiveness model was developed
using a decision tree. Two alternative strategies were evaluated:
prescription of a conventional NSAID or coxib. The UK General
Practice Research Database (GPRD) was used to estimate the
individual probabilities of upper gastrointestinal (GI) events
during current use of NSAID or coxib. Outcomes included upper
GI events as recorded in GPRD and hospitalisation for upper GI
events recorded in the national registry of hospitalisations (Hos-
pital Episode Statistics) linked to GPRD. Incremental prescrip-
tions costs were based on GPRD costs. RESULTS: The study
population included over 1 million patients prescribed conven-
tional NSAIDs or coxibs. Only a minority of patients used the
drugs long-term and daily (34.5% of conventional NSAIDs and
44.4% of coxibs), whereas coxib RCTs required daily use for at
least 6–9 months. The rate of upper GI events (as recorded in
GPRD) and hospitalisations during current use of conventional
NSAIDs decreased over calendar time with 5–8% per year (tests
for linear trend P-value < 0.05). The mean cost of preventing one
upper GI event as recorded in GPRD was £52 k (ranging from
£32 k with long-term daily use to £91 k with intermittent use)
and £149 k for hospitalisations. The mean costs (for GPRD
events) over calendar time were £29 k during 1990–1993 and
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